Competing risk analysis of site-specific cancer mortality for glargine exposure.

a<p>Although not shown here, the model also included age at first insulin prescription (FIP), gender, time between screening and FIP, treatment intensity level and all other available oral or insulin categories as both cumulative exposure and time-dependent ever exposed terms (see Methods).</p>b<p>SHR, subhazard ratios, similar to hazard ratios from the classic Cox regression.</p>c<p>Significant result rounded up to <0.05 due to very low estimated SHR.